Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r + 3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r + 2NUCs) at 96 weeks of follow-up. SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patie...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2017-01, Vol.72 (1), p.246-253
Main Authors: Perez-Molina, J A, Rubio, R, Rivero, A, Pasquau, J, Suárez-Lozano, I, Riera, M, Estébanez, M, Palacios, R, Sanz-Moreno, J, Troya, J, Mariño, A, Antela, A, Navarro, J, Esteban, H, Moreno, S
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anti-HIV Agents - adverse effects
Anti-HIV Agents - therapeutic use
Antiretroviral Therapy, Highly Active - adverse effects
Antiretroviral Therapy, Highly Active - methods
Female
Humans
Maintenance Chemotherapy - adverse effects
Maintenance Chemotherapy - methods
Male
Middle Aged
Treatment Outcome
Viral Load
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r + 3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r + 2NUCs) at 96 weeks of follow-up. SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients. Hepatitis B virus surface antigen-negative subjects with no previous treatment failure/resistance mutations and HIV-1-RNA
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/dkw379